Zhenfeng Duan • UCLA Profiles

Duan, Zhenfeng

Title(s)	Professor-in-Residence, Orthopaedic Surgery
Phone	3103191234
vCard	Download vCard

Bibliographic

Publications

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.

List All | Timeline

Zhao J, Dean DC, Hornicek FJ, Yu X, Duan Z. Emerging next-generation sequencing-based discoveries for targeted osteosarcoma therapy. Cancer Lett. 2020 Apr 01; 474:158-167. PMID: 31987920.

View in: PubMed
Thanindratarn P, Li X, Dean DC, Nelson SD, Hornicek FJ, Duan Z. Establishment and Characterization of a Recurrent Osteosarcoma Cell Line: OSA 1777. J Orthop Res. 2020 Apr; 38(4):902-910. PMID: 31736134.

View in: PubMed
Thanindratarn P, Dean DC, Nelson SD, Hornicek FJ, Duan Z. Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications. Cancer Treat Rev. 2020 Jan; 82:101934. PMID: 31794912.

View in: PubMed
Wei R, Dean DC, Thanindratarn P, Hornicek FJ, Guo W, Duan Z. Cancer Testis Antigens in Sarcoma: Expression, Function and Immunotherapeutic Application. Cancer Lett. 2019 Oct 18. PMID: 31634526.

View in: PubMed
Thanindratarn P, Dean DC, Nelson SD, Hornicek FJ, Duan Z. Advances in immune checkpoint inhibitors for bone sarcoma therapy. J Bone Oncol. 2019 Apr; 15:100221. PMID: 30775238.

View in: PubMed
Li X, Seebacher NA, Xiao T, Hornicek FJ, Duan Z. Targeting regulation of cyclin dependent kinase 9 as a novel therapeutic strategy in synovial sarcoma. J Orthop Res. 2019 02; 37(2):510-521. PMID: 30488489.

View in: PubMed
Ma H, Seebacher NA, Hornicek FJ, Duan Z. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma. EBioMedicine. 2019 Jan; 39:182-193. PMID: 30579871.

View in: PubMed
Dean DC, Shen S, Hornicek FJ, Duan Z. From genomics to metabolomics: emerging metastatic biomarkers in osteosarcoma. Cancer Metastasis Rev. 2018 12; 37(4):719-731. PMID: 30167827.

View in: PubMed
Wang J, Dean DC, Hornicek FJ, Shi H, Duan Z. RNA sequencing (RNA-Seq) and its application in ovarian cancer. Gynecol Oncol. 2019 01; 152(1):194-201. PMID: 30297273.

View in: PubMed
Li X, Seebacher NA, Hornicek FJ, Xiao T, Duan Z. Application of liquid biopsy in bone and soft tissue sarcomas: Present and future. Cancer Lett. 2018 12 28; 439:66-77. PMID: 30223067.

View in: PubMed
Wang J, Garbutt C, Ma H, Gao P, Hornicek FJ, Kan Q, Shi H, Duan Z. Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer. Gynecol Oncol. 2018 07; 150(1):143-150. PMID: 29699801.

View in: PubMed
Zhou Y, Shen JK, Yu Z, Hornicek FJ, Kan Q, Duan Z. Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma. Biochim Biophys Acta Mol Basis Dis. 2018 May; 1864(5 Pt A):1573-1582. PMID: 29452249.

View in: PubMed
Liu T, Shen JK, Choy E, Zhang Y, Mankin HJ, Hornicek FJ, Duan Z. CDK4 expression in chordoma: A potential therapeutic target. J Orthop Res. 2018 06; 36(6):1581-1589. PMID: 29194728.

View in: PubMed
Xiao X, Garbutt CC, Hornicek F, Guo Z, Duan Z. Advances in chromosomal translocations and fusion genes in sarcomas and potential therapeutic applications. Cancer Treat Rev. 2018 Feb; 63:61-70. PMID: 29247978.

View in: PubMed
Gao P, Seebacher NA, Hornicek F, Guo Z, Duan Z. Advances in sarcoma gene mutations and therapeutic targets. Cancer Treat Rev. 2018 Jan; 62:98-109. PMID: 29190505.

View in: PubMed